PEG-Irinotecan

聚乙二醇伊立替康

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NamePEG-Irinotecan
Drug Alias NameSSS-22JK-1201IJK1201I
ClassificationSmall molecules > Polymers and chelators
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsBrain metastasesSolid tumoursSmall Cell Lung Carcinoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShenyang Sunshine Pharmaceutical Co LtdTianjin Jenkem Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJenkem Tech Co LtdTianjin Jenkem Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsBrain metastasesSolid tumoursSmall Cell Lung Carcinoma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A